Randomized Trial: Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
7 Dec, 2018 | 01:30h | UTCCommentary: SABCS 2018: KATHERINE Trial: Adjuvant Ado-Trastuzumab Emtansine vs Trastuzumab in Early-Stage HER2-Positive Breast Cancer – The ASCO Post (free)